Patents by Inventor Timothy R. Wagenaar

Timothy R. Wagenaar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic RNA
    Patent number: 11865159
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 9, 2024
    Assignee: Sanofi
    Inventors: Friederike Gieseke, Ugur Sahin, Timothy R. Wagenaar, Dmitri G. Wiederschain, Christian Hotz
  • Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
    Publication number: 20220288199
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 15, 2022
    Applicant: SANOFI
    Inventors: Serena MASCIARI, Semra YORUK, Karl HSU, Timothy R. WAGENAAR, Nicolas ACQUAVELLA, Marie BERNARDO, Robert JABULOWSKY, Ugur SAHIN, Friederike GIESEKE, Zuzana JIRAKOVA TRNKOVA
  • Therapeutic RNA for Advanced Stage Solid Tumor Cancers
    Publication number: 20220040218
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 10, 2022
    Applicant: SANOFI
    Inventors: Serena Masciari, Semra Yoruk, Karl Hsu, Timothy R. Wagenaar, Nicolas Acquavella, Marie Bernardo, Robert Jabulowsky, Ugur Sahin, Friederike Gieseke, Zuzana Jirakova Trnkova
  • IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES
    Publication number: 20220016252
    Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Applicant: Synthorx, Inc.
    Inventors: Giovanni ABBADESSA, Carolina E. CAFFARO, Joseph LEVEQUE, Marcos MILLA, Jerod PTACIN, Timothy R. WAGENAAR
  • Therapeutic RNA
    Publication number: 20210290730
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 23, 2021
    Applicant: Sanofi
    Inventors: Friederike Gieseke, Ugur Sahin, Timothy R. Wagenaar, Dmitri G. Wiederschain
  • Therapeutic RNA
    Publication number: 20200147176
    Abstract: This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.
    Type: Application
    Filed: August 27, 2019
    Publication date: May 14, 2020
    Applicant: Sanofi
    Inventors: Friederike Gieseke, Ugur Sahin, Timothy R. Wagenaar, Dmitri G. Wiederschain